News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VBL Therapeutics Presents Positive Preclinical Data for VB-201 in Inflammatory Bowel Disease at Digestive Disease Week (DDW) 2012


5/21/2012 10:17:31 AM

TEL AVIV, Israel & SAN DIEGO--(BUSINESS WIRE)-- VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced data demonstrating VB-201 was found to be effective in attenuating inflammatory bowel disease (IBD) in preclinical models. VB-201 is a first-in-class, orally available disease-modifying agent selected from a series of proprietary oxidized phospholipid analogs pioneered by VBL in the Lecinoxoid molecular class. The results were presented today during a poster presentation at Digestive Disease Week (DDW) 2012 by Eyal Breitbart, Ph.D., vice president of research at VBL.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES